Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 65 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 M1m5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi3NkBp M2fqR2ROW09? M{PMeGlEPTB;MD6wNFAxPyEQvF2= MXyxO|k2PjB6MB?=
K562 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3yO|IhcA>? NWDKflBMTE2VTx?= M{fXb2lEPTB;MD6wNFEh|ryP NIrMdWoyPzl3NkC4NC=>
M07e NX7FS2RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fRSVczKGh? NYPnWWZnTE2VTx?= MkXLTWM2OD1yLkCwNVIh|ryP NVLVNGZmOTd7NU[wPFA>
ALL3 MWTDfZRwfG:6aXOgRZN{[Xl? M1TF[|AvOc7:TR?= NXr5XVJqPzJiaB?= M3zVOmROW09? MWrJR|UxRTBwMECwOEDPxE1? M{\UOlE6QDh7NUSw
CML MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfVNlAhdWmw NIToW41FVVOR Mkn1TWM2OD1yLkCwNUDPxE1? Ml\DNVkzOTlyMU[=
BA/F3 MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3NkBp MmXBSG1UVw>? M1LKO2lEPTB;Nj61PFkh|ryP NGnSUGszOzB6OE[0OC=>
BA/F3 NXjCUXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJO|IhcA>? NUHpZoVTTE2VTx?= M2\0UGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN NVPJRlhGOjNyOEi2OFQ>
BA/F3 NEXBTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[z[WRxPzJiaB?= NYrY[VJXTE2VTx?= M3zaNGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? NWfvdW9YOjNyOEi2OFQ>
BA/F3 M1TuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK3NkBp MUHEUXNQ Mnv6TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MXiyN|A5QDZ2NB?=
BA/F3 NVi0Slc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO3NkBp NUTKO5ZCTE2VTx?= NGe4U4NKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= M2Dl[lI{OzBzN{Cz
BA/F3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;0OVczKGh? NFmyfGhFVVOR M1G0VWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP NV\Ge49kOjN|MEG3NFM>
BA/F3 NYLHUI9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\3O|IhcA>? NFTLUlJFVVOR MlfTTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? MUeyN|MxOTdyMx?=
BA/F3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW3NkBp M2fXOmROW09? NWf1[lJVUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MX:yN|MxOTdyMx?=
BA/F3 MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvSO|IhcA>? NWHJUIlpTE2VTx?= MXrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? NFLsZVkzOzNyMUewNy=>
BA/F3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\POVc4OiCq NGrBc4xFVVOR Mk\xTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> M2jkWVI{OzBzN{Cz
BA/F3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPaW3V{PzJiaB?= NGr5Z|VFVVOR M3rHXWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP MlvKNlM{ODF5MEO=
BA/F3 NE\ycnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fJSlczKGh? MlP0SG1UVw>? NEnLUIpKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? M3[3cFI{OzBzN{Cz
BA/F3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz0dXU4OiCq MX3EUXNQ MWjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? M{\3TVI{OzBzN{Cz
T cell NH7Z[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp MmD4SG1UVw>? MUPJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> M{HwbVE4OTV2NUGy
WiDr NYHVbFZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i3fFczKGh? NGHC[pFFVVOR M4fsc2lEPTB;MD6wOVIh|ryP Ml7ZNVU3OTV3MUK=
PC3 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7TO|IhcA>? MnzSSG1UVw>? MV;JR|UxRTBwMEC5OEDPxE1? NIDRNJUyPTZzNUWxNi=>
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofXO|IhcA>? NVTSbFh{TE2VTx?= Mn\DTWM2OD1yLkCxNkDPxE1? Mlf1NVU3OTV3MUK=
Hs578T MX3DfZRwfG:6aXOgRZN{[Xl? NEnUOVQ4OiCq NHHaTJpFVVOR MnzoS2k2OD1yLkCzJO69VQ>? MmjVNlQxOTV|Mke=
HMEC MVvDfZRwfG:6aXOgRZN{[Xl? M3\DN|czKGh? M4jh[GROW09? NHXx[G1IUTVyPUGuPEDPxE1? MnTHNlQxOTV|Mke=
DU145 MV\DfZRwfG:6aXOgRZN{[Xl? NV7aTZpLPzJiaB?= MmPzSG1UVw>? NE\adYtIUTVyPUCuNVYh|ryP MUeyOFAyPTN{Nx?=
U251 NYXObIZnS3m2b4TvfIlkKEG|c3H5 MkHBO|IhcA>? MVHEUXNQ NHnBV5JIUTVyPUKuPFEh|ryP MVuyOFAyPTN{Nx?=
NCI60 NGPqcJJEgXSxdH;4bYMhSXO|YYm= M2TYNFczKGh? NXfZWYpkTE2VTx?= NWTtdo96T0l3ME21Mlch|ryP MlW0NlQxOTV|Mke=
MALME-3M NHvHfFNEgXSxdH;4bYMhSXO|YYm= MlP6O|IhcA>? MljXSG1UVw>? M3q1OGdKPTB;Nj62NUDPxE1? NXrkfHNrOjRyMUWzNlc>
KM12 MY\DfZRwfG:6aXOgRZN{[Xl? NX3KSYxnPzJiaB?= NGfpV|ZFVVOR NUfjUYloT0l3ME23MlQ1KM7:TR?= NYPqempVOjRyMUWzNlc>
SW620 NFvzVVVEgXSxdH;4bYMhSXO|YYm= M{LrXFczKGh? M1XPRWROW09? M1TWdmdKPTB;OD60N{DPxE1? MlvkNlQxOTV|Mke=
RXF 393NL MmDnR5l1d3SxeHnjJGF{e2G7 M17CNVQh\GG7cx?= MnHISG1UVw>? Ml35TWM2OD1yLkCyNVch|ryP MVOyN|I2OzB5NB?=
LXFA 983L Mm\3R5l1d3SxeHnjJGF{e2G7 NUnqdW4zPCCmYYnz M2Pae2ROW09? NGH6[29KSzVyPUCuNFU3PSEQvF2= NFvOclEzOzJ3M{C3OC=>
PRXF DU145 NGjkWnpEgXSxdH;4bYMhSXO|YYm= M4XKXVQh\GG7cx?= NYHxWo1kTE2VTx?= M1rFcGlEPTB;MD6wOlI{KM7:TR?= M3rx[VI{OjV|MEe0
PAXF 1657L NEnKdWJEgXSxdH;4bYMhSXO|YYm= Ml;kOEBl[Xm| MWTEUXNQ MW\JR|UxRTBwMUKxJO69VQ>? MVyyN|I2OzB5NB?=
CXF 1103L NFnCcolEgXSxdH;4bYMhSXO|YYm= NVWzO3BbPCCmYYnz MmW3SG1UVw>? NI\UeFZKSzVyPUSuN|Yh|ryP NXzHNmdmOjN{NUOwO|Q>
GXF251L M{jvVGN6fG:2b4jpZ{BCe3OjeR?= MoSzOEBl[Xm| MXPEUXNQ NF3WW41KSzVyPUKuNlUh|ryP MmPONlMzPTNyN{S=
NCI-H23 M1S4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfhdYk4OiCq MnvtSG1UVw>? M{Ww[mlEPTB;Mj6yO{DPxE1? MlHWNlM2OjFyMkC=
HCT116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XpS|czKGh? MmfFSG1UVw>? NGLzS3dKSzVyPUKuN{DPxE1? NGPBSXQzOzV{MUCyNC=>
MCF7 NYfoW4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp M3TvbmROW09? NGPzUGZKSzVyPUKuOVch|ryP MlXPNlM2OjFyMkC=
NCI-H460 NFG1V5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHxO|IhcA>? MnTMSG1UVw>? M1nQZWlEPTB;OD65PUDPxE1? M1vNOVI{PTJzMEKw
DLD1 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nQU|czKGh? NYLJcXVUTE2VTx?= M3jUNmlEPTB;ND62JO69VQ>? NGixdoQzOzV4N{m2NC=>
NCI-H661 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHSO|IhcA>? MoDXSG1UVw>? Ml7JTWM2OD15Lkig{txO Mn\3NlM2Pjd7NkC=
A549 NGTSSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK5fIs4OiCq MoX1SG1UVw>? MX\JR|UxRThwMjFOwG0> MYOyN|U3Pzl4MB?=
U937 M3u2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2niOFczKGh? Mm\FSG1UVw>? NG\HeGtKSzVyPUGyMlIh|ryP NIrNRlYzOzV4N{m2NC=>
HEK293 Ml[ySpVv[3Srb36gRZN{[Xl? M2rzPFExyqEQvF2= NIX1[GVFVVOR NULkd|hKUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> MoqyNlI4PzB4MUC=
HUVEC NV\h[JhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\uNE4yPcLizszN Mn3HO|IhcA>? NUTRRlFlTE2VTx?= NFzOWolKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MkLhNlI5PTN7OUO=
HUVEC MYDGeY5kfGmxbjDBd5NigQ>? M4H2e|E2yqEQvF2= NEDROYM4OiCq MWnEUXNQ M2m5W2lv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO NXPOTYM2OjJ6NUO5PVM>
Plasmodium falciparum NVrsellZTnWwY4Tpc44hSXO|YYm= M3r6eVExyqEQvF2= NI\ydFAyPSCvaX6= M1XZXmROW09? NGTvfVJKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? Mlu4NlQ2PTB|M{C=
PC3 Ml3jSpVv[3Srb36gRZN{[Xl? NEnneoExNjFizszN MY[1JIg> NUTyeo5rTE2VTx?= MnrsTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P MnG5NVk1PjJ7N{W=
DU145 M1zreGZ2dmO2aX;uJGF{e2G7 NYTjfJk3OC5zIN88US=> MmDZOUBp NGfp[WdFVVOR NXKzZ5pIUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0> MYixPVQ3Ojl5NR?=
PC3 M{HrTWtqdmG|ZTDBd5NigQ>? MVmwMlEh|ryP MnzKOUBp MnriSG1UVw>? NEf2U|VKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N M3PFPVE6PDZ{OUe1
DU145 M{TQeGtqdmG|ZTDBd5NigQ>? NEDINoYxNjFizszN M3zId|UhcA>? NH7TcldFVVOR M{fyfmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NFHBVm8yQTR4Mkm3OS=>
PC3 MkP4T4lv[XOnIFHzd4F6 MUOwMlEh|ryP NIfMN202KGh? MYrEUXNQ MWPJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NYHVO|lyOTl2NkK5O|U>
DU145 MkW5T4lv[XOnIFHzd4F6 Mly1NE4yKM7:TR?= MmXHOUBp Mn34SG1UVw>? NUnLfJFLUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= NYHzcnc1OTl2NkK5O|U>
Huh7 MkTlRY51cX[rcnHsJGF{e2G7 MlTJNk42KM7:TR?= M{PYelQh\GG7cx?= MUPEUXNQ MmnDTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP NH\JcIUyPzN4ME[3Oi=>
C6/36 MXzBcpRqfmm{YXygRZN{[Xl? NWe2WJFoOi53IN88US=> Mn[0OEBl[Xm| NX\vbJNXTE2VTx?= M2noSWlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MXmxO|M3ODZ5Nh?=
U937 M4f0NWZ2dmO2aX;uJGF{e2G7 NILUTYQyKM7:TR?= MV2xJIg> NYXpcHZ7TE2VTx?= MojoVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? MV2xO|Y5PDB7OR?=
U937 NXP2XVJrTnWwY4Tpc44hSXO|YYm= MlTxNUDPxE1? NWr2flRYOSCq NXTNbIF{TE2VTx?= NXvCXIxJWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? M{H6ZlE4Pjh2MEm5
murine mast cell NUPv[3dUTnWwY4Tpc44hSXO|YYm= MYWxJO69VQ>? MU[yOEBp M2TPd2ROW09? MWfJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? M{XFTVE4Pjh2MEm5
BV-173 NFPnbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLPTlhKSzVyPUCuNFAxODByMUC5JO69VQ>? NX:y[Vd2W0GQR1XS
K-562 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMECwNFAxOjZ4IN88US=> NUfaT21TW0GQR1XS
BL-70 NXT0cFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDQO2tzUUN3ME2wMlAxODByMEiyNkDPxE1? MkHXV2FPT0WU
EM-2 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvleHdHUUN3ME2wMlAxODByMUC4JO69VQ>? NET1VGFUSU6JRWK=
LAMA-84 NEP1S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMECwNFA{OjFizszN M3ThdHNCVkeHUh?=
MEG-01 M1THVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHlTWM2OD1yLkCwNFAxQThizszN Ml7mV2FPT0WU
EoL-1-cell MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPRfZdtUUN3ME2wMlAxODBzM{Gg{txO MnnBV2FPT0WU
CTV-1 NX;oeoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXDTWM2OD1yLkCwNFA1ODRizszN MXTTRW5ITVJ?
TE-15 NILSUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfCTWM2OD1yLkCwOVg6KM7:TR?= M1K5T3NCVkeHUh?=
NOS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHexOFlKSzVyPUCuNFA3OTNizszN NXzp[ZBLW0GQR1XS
D-336MG NW\VcYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXyeHRKSzVyPUCuNFA3OyEQvF2= MWDTRW5ITVJ?
LB1047-RCC NXLs[G9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnUOVBYUUN3ME2wMlAxQTh7IN88US=> MX7TRW5ITVJ?
LB996-RCC NXX1cYo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfjTWM2OD1yLkCwPVkyKM7:TR?= Ml3kV2FPT0WU
SW982 M2XC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[5TWM2OD1yLkCxNVE2KM7:TR?= NHriOVhUSU6JRWK=
TK10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXHTWM2OD1yLkCxNVc1KM7:TR?= MmjvV2FPT0WU
A704 NXXkT4NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEG0PVEh|ryP MVvTRW5ITVJ?
TE-8 M2LVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEG1O|Yh|ryP NUPBUmU1W0GQR1XS
DOHH-2 NHrMZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC4SXFTUUN3ME2wMlAyPzF7IN88US=> NIjvXI9USU6JRWK=
HOP-62 M4jmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HjVWlEPTB;MD6wNVg{PCEQvF2= MnTsV2FPT0WU
TE-12 NGXq[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvIdJNKSzVyPUCuNFE5PjFizszN NFvXUYxUSU6JRWK=
KGN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEG5OFIh|ryP NEjsR5BUSU6JRWK=
NCI-H1648 NXXnWnpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq2TWM2OD1yLkCyNFEyKM7:TR?= MoDxV2FPT0WU
OS-RC-2 NVr4elRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfpPWtQUUN3ME2wMlAzODNizszN MlnqV2FPT0WU
GB-1 NHG2SXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K3bmlEPTB;MD6wNlE2PyEQvF2= M13n[XNCVkeHUh?=
RXF393 NU\GbI4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEKzOVch|ryP NEjsW4ZUSU6JRWK=
LC-2-ad NVvM[oJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ZTIxKSzVyPUCuNFI2QDZizszN NHi0[YxUSU6JRWK=
KS-1 NEP0V|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEK3N{DPxE1? NX\uXWJiW0GQR1XS
ETK-1 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljWTWM2OD1yLkCyPFMzKM7:TR?= MYPTRW5ITVJ?
SW954 NHPjbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT1TWM2OD1yLkCyPVI4KM7:TR?= MmHxV2FPT0WU
Becker M3zHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEOwNFMh|ryP MVnTRW5ITVJ?
MZ1-PC MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEOxNVkh|ryP Ml\mV2FPT0WU
ES6 M3HJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MontTWM2OD1yLkCzNVk{KM7:TR?= MmLwV2FPT0WU
KURAMOCHI Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P3VWlEPTB;MD6wN|Q5PyEQvF2= M{C4Z3NCVkeHUh?=
CGTH-W-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEO1OFgh|ryP MV;TRW5ITVJ?
VA-ES-BJ NVvPNZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjXc45[UUN3ME2wMlA{QTB{IN88US=> M1HoO3NCVkeHUh?=
LXF-289 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M361SmlEPTB;MD6wN|k2PiEQvF2= MV7TRW5ITVJ?
MPP-89 M{L4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTqb4c2UUN3ME2wMlA1ODR7IN88US=> MnziV2FPT0WU
SW872 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CwXWlEPTB;MD6wOFE3OSEQvF2= MVrTRW5ITVJ?
SNB75 NU[wcHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXRS3VNUUN3ME2wMlA1PDN3IN88US=> NHTrb45USU6JRWK=
PSN1 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHXUmdKSzVyPUCuNFQ1PzRizszN NG[yT|NUSU6JRWK=
LB831-BLC NXnZT2VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PiNWlEPTB;MD6wOFYxQSEQvF2= NGHN[nBUSU6JRWK=
MFH-ino M37HXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPPbIVHUUN3ME2wMlA1PzJ2IN88US=> M3myeHNCVkeHUh?=
TGBC24TKB NGTDdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKzSmdGUUN3ME2wMlA1PzZzIN88US=> MmXJV2FPT0WU
A388 NFLFPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni1TWM2OD1yLkC1NFk2KM7:TR?= MVTTRW5ITVJ?
BB30-HNC MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3oTWM2OD1yLkC1OFM4KM7:TR?= M1TWZ3NCVkeHUh?=
GI-ME-N NIflNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrGNW9SUUN3ME2wMlA3OTF6IN88US=> M3TFUnNCVkeHUh?=
TGBC1TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rIXGlEPTB;MD6wOlE3PCEQvF2= MmryV2FPT0WU
TE-10 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorKTWM2OD1yLkC2N|U4KM7:TR?= M1;2XHNCVkeHUh?=
A498 NGfQRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[xTWM2OD1yLkC3Nlg1KM7:TR?= NFLBRnlUSU6JRWK=
TE-11 NWPzfXN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHaXFNrUUN3ME2wMlA4QDV6IN88US=> M2DUUnNCVkeHUh?=
BB65-RCC M17qXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXYN|dKSzVyPUCuNFgzOjdizszN MUTTRW5ITVJ?
C2BBe1 NWexR5ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEizNFgh|ryP MnPHV2FPT0WU
NCI-H747 M3zYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEizOlIh|ryP MX7TRW5ITVJ?
IST-MES1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEi1OVIh|ryP MlnYV2FPT0WU
KALS-1 NHK4fGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrkVIJwUUN3ME2wMlA6PDlizszN NETrOGlUSU6JRWK=
GCIY MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPvTWM2OD1yLkC5OlU3KM7:TR?= NF3uT3JUSU6JRWK=
RL95-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PMOWlEPTB;MD6xNFM5KM7:TR?= MWnTRW5ITVJ?
TE-1 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXOVIVEUUN3ME2wMlExPTRizszN NGHj[29USU6JRWK=
NCI-H1355 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\kTWM2OD1yLkGxNFI5KM7:TR?= MkfxV2FPT0WU
SW962 NFnPXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;iVWlEPTB;MD6xNVI6OiEQvF2= M4SyNXNCVkeHUh?=
KLE NWTxdZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMUGzNVch|ryP M4nHZnNCVkeHUh?=
MC116 NUPNTVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXmdlZJUUN3ME2wMlEyPDFizszN MXrTRW5ITVJ?
NMC-G1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IeHlKSzVyPUCuNVE3ODZizszN M{LpXHNCVkeHUh?=
KU812 NGrySmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMUG4PFMh|ryP NYLUZYxtW0GQR1XS
COLO-829 NULYRVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[4VGlEPTB;MD6xNlIyOyEQvF2= NH\HRXlUSU6JRWK=
NTERA-S-cl-D1 NX2yUWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS5ZoM6UUN3ME2wMlEzOjh|IN88US=> M{DBT3NCVkeHUh?=
IST-MEL1 NXLFNYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfJNmlKSzVyPUCuNVM1PSEQvF2= MWTTRW5ITVJ?
MLMA NYDI[mhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\HOnFNUUN3ME2wMlE1ODN{IN88US=> M{HBWXNCVkeHUh?=
LS-123 NFfLNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvvTHNWUUN3ME2wMlE1ODZ2IN88US=> MXnTRW5ITVJ?
LB2518-MEL M{DnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMUSxOlIh|ryP MVTTRW5ITVJ?
NB69 NGTacZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMUS0N|Yh|ryP M3LFcHNCVkeHUh?=
8-MG-BA NXT4OZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMUW0OVgh|ryP NYnQOIF2W0GQR1XS
K5 NF\m[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPTOWFpUUN3ME2wMlE3PDh7IN88US=> NV;keod6W0GQR1XS
KINGS-1 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMU[2OlYh|ryP MV;TRW5ITVJ?
SF268 NH\CSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfSd2ZKSzVyPUCuNVc1ODRizszN M1PHNXNCVkeHUh?=
PF-382 NWLYbpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof1TWM2OD1yLkG3Olc5KM7:TR?= M2HMcHNCVkeHUh?=
SH-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnVRWh{UUN3ME2wMlE5PDF|IN88US=> M1H3dXNCVkeHUh?=
NALM-6 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fTVGlEPTB;MD6xPVI6PSEQvF2= NYKx[XI5W0GQR1XS
CP66-MEL NGPlPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWyTWM2OD1yLkG5OVMyKM7:TR?= M2XyOHNCVkeHUh?=
697 M2ewSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMUm5PFch|ryP MVPTRW5ITVJ?
CP67-MEL NFPHcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfkTWM2OD1yLkKwOFg5KM7:TR?= MXTTRW5ITVJ?
DSH1 M3PEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrXGpKSzVyPUCuNlQxODFizszN MlLUV2FPT0WU
HCE-4 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPUTWM2OD1yLkK2OFM6KM7:TR?= NELRNIFUSU6JRWK=
MZ2-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMki1N|ch|ryP NXrsdZRNW0GQR1XS
BL-41 M2q5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\wV5dKSzVyPUCuNlkyOjNizszN MUTTRW5ITVJ?
HUTU-80 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzNTWM2OD1yLkOxOFIh|ryP NF\C[XhUSU6JRWK=
LOXIMVI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrCTWM2OD1yLkOxOVA{KM7:TR?= MYXTRW5ITVJ?
no-10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryTWM2OD1yLkOxPVMyKM7:TR?= NYrLb2NDW0GQR1XS
KARPAS-422 NIThUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLye4d5UUN3ME2wMlM{QTl5IN88US=> NVTpdZVNW0GQR1XS
SW684 M4LJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwM{S5PEDPxE1? MmK3V2FPT0WU
SF126 NFnzfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDHc2dsUUN3ME2wMlM2PDFizszN MWTTRW5ITVJ?
D-263MG NEC5[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwM{[yNlQh|ryP M2myOnNCVkeHUh?=
OVCAR-4 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLBTWM2OD1yLkO3OFM{KM7:TR?= NF\IPXlUSU6JRWK=
BB49-HNC M{LIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnmTWM2OD1yLkO4OVk6KM7:TR?= MY\TRW5ITVJ?
ONS-76 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG2TWM2OD1yLkSyPVUyKM7:TR?= MnTwV2FPT0WU
MZ7-mel NVPMN|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\pOWlEPTB;MD60O|kyOSEQvF2= NEPnNoxUSU6JRWK=
RCC10RGB NFfPUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrueHVKSzVyPUCuOFkyOSEQvF2= M{P0[HNCVkeHUh?=
BOKU M{P0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrB[mhKSzVyPUCuOFkyOzNizszN M{O3RnNCVkeHUh?=
no-11 NGfLTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzTWWxKSzVyPUCuOVAzOjhizszN M2XZZXNCVkeHUh?=
IST-SL2 NXLTR25GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnCeWJKSzVyPUCuOVA{ODJizszN NE\sSFdUSU6JRWK=
RKO MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNUK5OlYh|ryP NHjOcIlUSU6JRWK=
HT-144 M1e4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNUO2NFkh|ryP M1\ERnNCVkeHUh?=
NCI-H446 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNkK3OkDPxE1? NITKc3FUSU6JRWK=
QIMR-WIL NF63Nm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDjeldKSzVyPUCuO|A3OjlizszN NGPpVXdUSU6JRWK=
MHH-PREB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHuNHpKSzVyPUCuO|Q1PjlizszN MWXTRW5ITVJ?
EW-16 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwN{[xO|gh|ryP M3W0R3NCVkeHUh?=
EW-24 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHMTWM2OD1yLke4NVY2KM7:TR?= MUHTRW5ITVJ?
LB373-MEL-D M{\GeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSwcVZKSzVyPUCuPFI2ODhizszN NXHFc2pQW0GQR1XS
TE-9 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\lTWM2OD1yLki3OVMzKM7:TR?= MlnSV2FPT0WU
A3-KAW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ITWM2OD1yLkm4OFUzKM7:TR?= NVe2UlB2W0GQR1XS
A101D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPEeWpyUUN3ME2xMlA{ODR|IN88US=> NW\Yb2UzW0GQR1XS
OCUB-M MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXaOWJXUUN3ME2xMlA1PDF{IN88US=> MWfTRW5ITVJ?
ES4 M2rxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrvbG5UUUN3ME2xMlA2OTR3IN88US=> MWPTRW5ITVJ?
TE-6 M2r2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPDTWM2OD1zLkKxNlI3KM7:TR?= MUDTRW5ITVJ?
D-502MG M1rmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDjTWM2OD1zLkKzN|c3KM7:TR?= NVfSN212W0GQR1XS
KNS-42 NUPXSI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwMkS0NVIh|ryP MkD0V2FPT0WU
SNU-C2B NESwR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXoTWM2OD1zLkOwOVg6KM7:TR?= NVv3bZd7W0GQR1XS
NCI-H1838 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwM{C3N|Mh|ryP M1GwPHNCVkeHUh?=
NKM-1 NYDzXHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfuSnpKSzVyPUGuN|A5PTlizszN NWLyUlg3W0GQR1XS
GI-1 M1voTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml31TWM2OD1zLkO2NlIh|ryP NF3CVm1USU6JRWK=
NB5 M{DQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwM{m4Nlch|ryP Ml;4V2FPT0WU
CAS-1 M3v2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnQTWM2OD1zLkSwPVkzKM7:TR?= NH\6bHNUSU6JRWK=
HCE-T M3jYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKxTWM2OD1zLkW2O|E1KM7:TR?= NYPuR|I6W0GQR1XS
SBC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TTWM2OD1zLkW3PVg1KM7:TR?= MkjVV2FPT0WU
JiyoyeP-2003 M3i2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwN{O0OlYh|ryP M2\wcHNCVkeHUh?=
TE-5 M3;qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwN{mxN|kh|ryP NY[0TFN2W0GQR1XS
CAN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe0XGRKSzVyPUGuPFIzPTJizszN MmfIV2FPT0WU
SK-UT-1 NW\QOWRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PwW2lEPTB;Mj6xOlY6OyEQvF2= NWK2NWREW0GQR1XS
JVM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELhdFVKSzVyPUKuN|YzQDRizszN NUX1dGpJW0GQR1XS
LB771-HNC NXTpZYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwNUe1OVEh|ryP NHfrS5BUSU6JRWK=
NCCIT NGjxbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T5SWlEPTB;Mj64OlYyPiEQvF2= NW\0WW8zW0GQR1XS
NCI-H2126 M4PBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwOEe1OVIh|ryP MVXTRW5ITVJ?
Calu-6 NGDHN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3YUVhRUUN3ME2zMlA2PzRzIN88US=> NIS4cW1USU6JRWK=
SK-LMS-1 M{iyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwMUG4PFYh|ryP MULTRW5ITVJ?
ARH-77 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNwNE[5NVUh|ryP NHX2WlRUSU6JRWK=
NB17 NHvIdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MleyTWM2OD1|Lk[zPFQ4KM7:TR?= NYHW[lFFW0GQR1XS
A253 NV\4SYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwN{OyOFYh|ryP NUXOZlJiW0GQR1XS
OPM-2 NX\UcXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrje4FKSzVyPUSuNlc3QDVizszN NGnTWYpUSU6JRWK=
MV-4-11 NWr4c3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHFc41KSzVyPUSuN|Y1PTRizszN Mnz5V2FPT0WU
SR MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq4NGdKSzVyPUSuOFk6PTRizszN MlP0V2FPT0WU
KG-1 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkniTWM2OD12Lk[wPFQ2KM7:TR?= M3fkOXNCVkeHUh?=
OCI-AML2 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD13Lki2NVU1KM7:TR?= MlTjV2FPT0WU
D-247MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTVRYJsUUN3ME22MlEzPTF7IN88US=> MWHTRW5ITVJ?
DJM-1 NFnydWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\V[2lEPTB;Nj60PFU2QCEQvF2= MnG4V2FPT0WU
RPMI-6666 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WySmlEPTB;Nz6yO|A3PyEQvF2= MkjFV2FPT0WU
KARPAS-45 NH23VGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrLd|h7UUN3ME23MlUyPjdzIN88US=> MXjTRW5ITVJ?
LP-1 NVPPT2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\kTWM2OD15LkW0O|gzKM7:TR?= MUDTRW5ITVJ?
RS4-11 NV;wSIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPJc3NlUUN3ME23MlY2Pzh5IN88US=> MlLMV2FPT0WU
DU-4475 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjl[VRKSzVyPUiuNlE3PTJizszN M{fyXHNCVkeHUh?=
MONO-MAC-6 NFzyc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwMkewOlYh|ryP MVXTRW5ITVJ?
NCI-SNU-16 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfETWM2OD16LkW2NVI5KM7:TR?= NUHaU2Y5W0GQR1XS
SJSA-1 NFr4eVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDBS|Z{UUN3ME24MlczQDB3IN88US=> NELU[I9USU6JRWK=
MMAC-SF NV25bpQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLITWM2OD16Lke5N|A4KM7:TR?= MWDTRW5ITVJ?
SK-NEP-1 NWHTRVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;0OWt6UUN3ME24Mlg6OTV3IN88US=> NVjJ[mNGW0GQR1XS
J-RT3-T3-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXxUpdKSzVyPUiuPVY2OjlizszN MWTTRW5ITVJ?
SKM-1 M4rQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjt[ohKSzVyPUmuNFE4OzRizszN Mmm4V2FPT0WU
LB2241-RCC M3j5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjkTWM2OD17LkCyNFEzKM7:TR?= NVu2fnJjW0GQR1XS
SIG-M5 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LPU2lEPTB;OT6wNlQ6OyEQvF2= NInCTpBUSU6JRWK=
EVSA-T MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:1fGlEPTB;OT6yO|c6OyEQvF2= NWPofmgxW0GQR1XS
GT3TKB M2jZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLRTWM2OD17LkO1OVQ3KM7:TR?= MnfwV2FPT0WU
NB6 M{jYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\xTWM2OD17LkmyNlU6KM7:TR?= NF71SY1USU6JRWK=
EHEB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TGTmlEPTB;MUCuNFY2PiEQvF2= MULTRW5ITVJ?
HEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFyLkS3O|Yh|ryP NFvRWJpUSU6JRWK=
ALL-PO NEnoPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFyLke5N|gh|ryP M3TZ[3NCVkeHUh?=
TGW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD1zMT6yPFI5KM7:TR?= MkSyV2FPT0WU
BC-3 NGnF[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT3TWM2OD1zMj6xNVM5KM7:TR?= NIr2PJlUSU6JRWK=
IA-LM Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPJeJNKSzVyPUGyMlQ1PDVizszN MYHTRW5ITVJ?
UACC-257 NFX0UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PocWlEPTB;MUKuPVE6QCEQvF2= NIDu[YpUSU6JRWK=
KP-N-YS NXT5VY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvUXFZKSzVyPUGyMlkzQDNizszN M1TxSXNCVkeHUh?=
Raji MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXhS|M2UUN3ME2xN{44PDl5IN88US=> NITPeXVUSU6JRWK=
SF539 NXfqN|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjRSIJPUUN3ME2xN{45PTV5IN88US=> M1:yWXNCVkeHUh?=
DMS-153 M4DRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHCdWVMUUN3ME2xOE4xODJ6IN88US=> NEHx[GdUSU6JRWK=
L-540 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzuS4lKSzVyPUG1MlA3PzJizszN M4rzeHNCVkeHUh?=
MN-60 M4\yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLsSJdKSzVyPUG1MlE6PzlizszN MXzTRW5ITVJ?
RPMI-8866 M4HWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDsVo9WUUN3ME2xO{41PDV2IN88US=> NIjTUoxUSU6JRWK=
NCI-H510A NUnBT3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF7LkO5O|Mh|ryP NEfC[lJUSU6JRWK=
NB13 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqyXHBbUUN3ME2xPU41QDd5IN88US=> M4LrO3NCVkeHUh?=
HAL-01 NF3KPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;aTWM2OD1zOT63OVQ{KM7:TR?= MWrTRW5ITVJ?
NCI-H720 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHIUZNxUUN3ME2yNE4zPzN|IN88US=> M4C3fHNCVkeHUh?=
REH MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTETWM2OD1{MD62N|U4KM7:TR?= NYDEVHV5W0GQR1XS
KNS-81-FD MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zGU2lEPTB;MkOuNVQ3KM7:TR?= NGHwWpZUSU6JRWK=
HC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ2LkW1OVEh|ryP MkTPV2FPT0WU
NCI-H2141 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPlW3RKSzVyPUK0Mlc4PTRizszN M4j6VXNCVkeHUh?=
MOLT-4 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjOmNKSzVyPUK2MlY4PTNizszN MlrPV2FPT0WU
OMC-1 NHXiR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHCTWM2OD1{Nz6xOFIzKM7:TR?= MV7TRW5ITVJ?
LC-1F NG\1T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j1OmlEPTB;MkeuN|I1PSEQvF2= M{T0XHNCVkeHUh?=
NCI-H1304 M4j2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ6LkG2Nlgh|ryP MnfIV2FPT0WU
BC-1 NIjBe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HwTmlEPTB;MkiuOlUyKM7:TR?= M3G2XnNCVkeHUh?=
NCI-H64 NHvtXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ7Lk[yOVMh|ryP NWOxOXhMW0GQR1XS
MOLT-16 NYrJNJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfodo1MUUN3ME2yPU43Ojl{IN88US=> NUDPNlVQW0GQR1XS
U-87-MG MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfXZpg5UUN3ME2zNE44PjZizszN Mk\KV2FPT0WU
GAK MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNzLkK2PFYh|ryP M1vKTnNCVkeHUh?=
ES8 M{LCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHSTWM2OD1|Mj6xNlUzKM7:TR?= NUniOWFiW0GQR1XS
HCC1599 NXToUlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvTU|B{UUN3ME2zNk4{OzJ3IN88US=> M4rEZnNCVkeHUh?=
EB-3 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHHPGZnUUN3ME2zOE4{OTF5IN88US=> NELsPG9USU6JRWK=
HCC1187 M2\Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjEUmRWUUN3ME2zOU45ODV{IN88US=> NHKzXlhUSU6JRWK=
SK-PN-DW M4X1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DOcmlEPTB;M{[uNVk1OyEQvF2= MYnTRW5ITVJ?
JVM-3 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfZV|hkUUN3ME2zO{4zOzN6IN88US=> NG\6Nm5USU6JRWK=
HCC2157 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXSTWM2OD1|Nz65PVQ3KM7:TR?= Mkm4V2FPT0WU
A4-Fuk NXrPTZRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnoNJFJUUN3ME2zPE4yODB7IN88US=> MkizV2FPT0WU
COR-L279 NXXpTZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTRyLkK4OVEh|ryP M4fSSnNCVkeHUh?=
DEL MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLuTWM2OD12MT65NFg3KM7:TR?= NGrGOY5USU6JRWK=
NCI-H1395 M3freWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTR{LkCxOlMh|ryP NILD[olUSU6JRWK=
MHH-NB-11 NUXISnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHEZld1UUN3ME20N{4xQDF6IN88US=> NXTINZlCW0GQR1XS
NCI-H2107 M1HDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XUe2lEPTB;NEOuOFg1PiEQvF2= MmTBV2FPT0WU
NEC8 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR2LkOzOkDPxE1? MXLTRW5ITVJ?
COLO-684 NWWwSZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ITWM2OD12Nj6yNlU5KM7:TR?= M2nvWHNCVkeHUh?=
LS-411N M4n2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PvWmlEPTB;NEiuOFc1QCEQvF2= MljwV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID